247 related articles for article (PubMed ID: 23643805)
1. HER-2 overexpression is not associated with increased ipsilateral breast tumor recurrence in DCIS treated with breast-conserving surgery followed by radiotherapy.
Noh JM; Lee J; Choi DH; Cho EY; Huh SJ; Park W; Nam SJ; Lee JE; Kil WH
Breast; 2013 Oct; 22(5):894-7. PubMed ID: 23643805
[TBL] [Abstract][Full Text] [Related]
2. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.
Halasz LM; Sreedhara M; Chen YH; Bellon JR; Punglia RS; Wong JS; Harris JR; Brock JE
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e581-6. PubMed ID: 22208975
[TBL] [Abstract][Full Text] [Related]
3. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
[TBL] [Abstract][Full Text] [Related]
5. Comparison of ipsilateral breast tumor recurrence after breast-conserving surgery between ductal carcinoma in situ and invasive breast cancer.
Choi YJ; Shin YD; Song YJ
World J Surg Oncol; 2016 Apr; 14():126. PubMed ID: 27122132
[TBL] [Abstract][Full Text] [Related]
6. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
[TBL] [Abstract][Full Text] [Related]
7. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
Barnes NL; Khavari S; Boland GP; Cramer A; Knox WF; Bundred NJ
Clin Cancer Res; 2005 Mar; 11(6):2163-8. PubMed ID: 15788662
[TBL] [Abstract][Full Text] [Related]
8. Mammographically detected, clinically occult ductal carcinoma in situ treated with breast-conserving surgery and definitive breast irradiation.
Solin LJ; McCormick B; Recht A; Haffty BG; Taylor ME; Kuske RR; Bornstein BA; McNeese M; Schultz DJ; Fowble BL; Barrett W; Yeh IT; Kurtz JM; Amalric R; Fourquet A
Cancer J Sci Am; 1996; 2(3):158-65. PubMed ID: 9166516
[TBL] [Abstract][Full Text] [Related]
9. Concurrent lobular neoplasia increases the risk of ipsilateral breast cancer recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy.
Rudloff U; Brogi E; Brockway JP; Goldberg JI; Cranor M; Wynveen CA; Nehhozina T; Reiner AS; Patil S; Van Zee KJ
Cancer; 2009 Mar; 115(6):1203-14. PubMed ID: 19170233
[TBL] [Abstract][Full Text] [Related]
10. Factors predicting in-breast tumor recurrence after breast-conserving surgery.
Mechera R; Viehl CT; Oertli D
Breast Cancer Res Treat; 2009 Jul; 116(1):171-7. PubMed ID: 18815880
[TBL] [Abstract][Full Text] [Related]
11. Ipsilateral local recurrence in relation to therapy and morphological characteristics in patients with ductal carcinoma in situ of the breast.
Ringberg A; Idvall I; Fernö M; Anderson H; Anagnostaki L; Boiesen P; Bondesson L; Holm E; Johansson S; Lindholm K; Ljungberg O; Ostberg G
Eur J Surg Oncol; 2000 Aug; 26(5):444-51. PubMed ID: 11016463
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Significance of Clinicopathologic Features in Patients With Breast Ductal Carcinoma-in-Situ Who Received Breast-Conserving Surgery.
Kuo SH; Lo C; Chen YH; Lien HC; Kuo WH; Wang MY; Lee YH; Huang CS
Clin Breast Cancer; 2018 Dec; 18(6):441-450.e2. PubMed ID: 29709458
[TBL] [Abstract][Full Text] [Related]
13. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
14. Metastatic invasive breast cancer recurrence following curative-intent therapy for ductal carcinoma in situ.
Al Mushawah F; Rastelli A; Pluard T; Margenthaler JA
J Surg Res; 2012 Mar; 173(1):10-5. PubMed ID: 21696764
[TBL] [Abstract][Full Text] [Related]
15. Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women.
Rodrigues NA; Dillon D; Carter D; Parisot N; Haffty BG
Cancer; 2003 Mar; 97(6):1393-403. PubMed ID: 12627502
[TBL] [Abstract][Full Text] [Related]
16. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
[TBL] [Abstract][Full Text] [Related]
18. Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast.
Boland GP; McKeown A; Chan KC; Prasad R; Knox WF; Bundred NJ
Br J Cancer; 2003 Jul; 89(2):277-83. PubMed ID: 12865917
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
[TBL] [Abstract][Full Text] [Related]
20. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.
Margalit DN; Sreedhara M; Chen YH; Catalano PJ; Nguyen PL; Golshan M; Overmoyer BA; Harris JR; Brock JE
Ann Surg Oncol; 2013 Mar; 20(3):811-8. PubMed ID: 22956068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
